ViaCyte to Present at Upcoming Healthcare Events
SAN DIEGO, March 14, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced three presentations at upcoming healthcare events.
Details of the presentations are as follows:
Event: Keystone Symposia: Stem Cells and Regeneration in the Digestive Organs
Session: Developmental Origin of Stem Cells
Title: Stem-Cell Derived, Macroencapsulated Islet Replacement for Type 1 Diabetes
Speaker: Dr. Olivia G. Kelly, Senior Director, Cell Biology
Date/Time: March 17, 9:00 a.m. to 11:15 a.m. MDT
Location: Keystone Resort, Keystone, Colorado
Event: Alliance for Regenerative Medicine 4th Annual Cell & Gene Therapy Investor Day
Speaker: Dr. Paul Laikind, President and CEO
Date/Time: March 22, 4:20 p.m. EDT
Location: Metropolitan Club, New York, New York
Event: CiRA/ISSCR 2016 International Symposium – Pluripotency: From Basic Science to Therapeutic Applications
Session: Session 4: Therapeutic Application II
Speaker: Dr. Allan Robins, Senior Vice President, Science and Technology
Date/Time: March 24, 9:00 a.m. JST
Location: Kyoto University, Kyoto, Japan
ViaCyte’s VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes. More info on the clinical trial is here: https://clinicaltrials.gov/ct2/show/NCT02239354.
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goal of reducing the risk of hypoglycemia and diabetes-related complications without requiring long-term immune suppression.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.